Functional and morphological cardiac changes in myeloproliferative disorders (clinical study)

Kadıköylü, Gürhan; Onbasili, Alper; Tekten, Tarkan; Barutça, Sabri; Bolaman, Zahit

doi:10.1016/j.ijcard.2003.08.013

Cited by 16 publications

(21 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The final selection included 3 case series, 7‐9 7 prospective cohort studies, 10‐16 5 Retrospective cohort studies, 4,5,17‐19 1 descriptive study based on clinical records, 3 and 1 case‐control study 20 . A summary of study characteristics is shown in Table 1.…”

Section: Resultsmentioning

confidence: 99%

Prevalence and risk factors for Pulmonary Hypertension associated with chronic Myeloproliferative Neoplasms

Ferrari

Scandura

Masciulli

et al. 2020

European J of Haematology

View full text Add to dashboard Cite

Objectives Pulmonary hypertension (PH) is commonly reported in Philadelphia‐chromosome negative myeloproliferative neoplasms (MPNs) including polycythemia vera (PV), essential thrombocythemia (ET), and myelofibrosis (MF). PH may be diagnosed directly by right heart catheterization (RHC) or estimated by transthoracic echocardiography (TTE). Survival is shortened by PH but despite the potential significance of PH to management and prognosis of MPN, estimates of its prevalence in MPNs vary and risk factors for the condition are poorly established. We performed a systematic review and meta‐analysis of available studies to fill this void. Methods We searched EMBASE, MEDLINE, and Clinicaltrials.gov for the terms “pulmonary hypertension,” “myeloproliferative disorders,” “polycythemia vera,” “essential thrombocythemia,” and “myelofibrosis.” We restricted analysis to the 1999‐2019 window to improve uniformity of MPN diagnostic criteria. We retrieved 221 records and, after abstract and full‐text screening, identified 17 papers meeting criteria for inclusion in our meta‐analysis. A modified Newcastle‐Ottawa scale was used to assess quality. Results Results for 935 patients were available, 309 of these having PH (33%). Using logistic mixed‐effect regression, we found that diagnosis mode (RHC vs TTE) and MPN duration influenced PH prevalence. Studies employing predominantly TTE yielded prevalence estimates ~5‐fold higher than those using RHC (35% vs 7.2%). We identified MF and duration of MPN as significant risk factors for development of PH. Conclusions Prevalence of PH in MPNs is poorly understood with estimates ranging from 3.8% to 58%. Patients with MF and longer duration of disease seem at particularly high risk and should be carefully monitored for PH.

show abstract

Section: Resultsmentioning

confidence: 99%

Prevalence and risk factors for Pulmonary Hypertension associated with chronic Myeloproliferative Neoplasms

Ferrari

Scandura

Masciulli

et al. 2020

European J of Haematology

View full text Add to dashboard Cite

show abstract

“…This finding is similar to those of other studies. 9 , 29 Anemia can be explained by the fact that CML patients have poor oral intake, and therefore often suffer from nutritional anemia, reflecting either iron deficiency anemia or megaloblastic anemia. In addition, patients with CML may also have anemia due to chronic disease.…”

Section: Discussionmentioning

confidence: 99%

“…Cardiac abnormalities, including coronary arterial thrombosis, myocardial infarction, pulmonary hypertension (PHT), asymptomatic pericardial effusion, cardiac tamponade, intractable cardiac failure due to intraventricular thrombosis, and valvular heart diseases, have been associated with CML. 8 , 9 Additionally, cardiac abnormalities may also be associated with the use of imatinib. Given the impact of cardiovascular abnormalities in the general population, cardiac abnormalities may contribute to the morbidity and mortality observed in patients with CML.…”

Section: Introductionmentioning

confidence: 99%

Comparative Assessment of Echocardiographic Patterns Among Chronic Myeloid Leukemia Patients on Tyrosine Kinase Inhibitor and Healthy Controls

Bamgboje¹,

Durosinmi²,

Mene-Afejuku³

et al. 2022

VHRM

View full text Add to dashboard Cite

Purpose Chronic myeloid leukemia (CML) is one of the common hematological malignancies in Nigeria. Cardiac abnormalities are associated with CML irrespective of treatment with tyrosine kinase inhibitors such as imatinib, which is available gratis in Nigeria. Objective To assess the prevalence and patterns of cardiac dysfunction among patients with CML irrespective of treatment with imatinib using transthoracic echocardiography, and 12-lead surface electrocardiography. Patients and Methods CML patients without Imatinib, CML patients with imatinib, and apparently healthy (age- and sex-matched) controls were 70 each in the study. Various echocardiographic parameters were measured and data obtained were analyzed, and the level of significance was taken as p < 0.05. Results Of 70 CML patients with imatinib, 54.3% were men and 45.7% were women, while the CML group without imatinib had 62.9% men and 37.1% women, non-CML control had 54.3% men and 45.7% women. The average hematocrit was significantly lower in the CML group without Imatinib compared with the other groups (p<0.001). And, 12.9% and 17.1% of CML groups with and without imatinib had LVH, respectively, and none of the non-CML controls had LVH (P<0.041). Impaired left ventricular relaxation in 25.71% and 28.57% of CML patients with and without imatinib respectively but only 8.57% of the non-CML control had impaired left ventricular relaxation (p=0.236). Mitral valve regurgitation was the most frequent valvular abnormality across the groups. Pulmonary hypertension in 17.4% and 20% of CML patients with and without imatinib, respectively, but none of the non-CML controls had pulmonary hypertension (p<0.001). Pericardial effusion in 32.86% and 45.71% of CML patients with and without imatinib, respectively, but none of the non-CML controls had pericardial effusion (p<0.001). There was no significant difference in the QTC interval across the three groups. Conclusion Cardiac abnormalities are present in CML patients with or without Imatinib treatment, with significant prevalence than what is seen in the non-CML control group.

show abstract

“…PH represents the most prominent cardiac disorder in myeloproliferative disorders and is more frequent in the subset of patients with previous thrombotic events, having a high number of platelets, diagnosed with MMM, or chronic myelogenous leukemia [5].…”

Section: Discussionmentioning

confidence: 99%

“…The presence of PH together with portal hypertension with or without chronic liver disease is referred as portopulmonary hypertension (PPH). Although PPH is a complication of chronic liver disease and occurs in 2-3% of patients with portal hypertension, the association of PPH with MMM is very rare [5]. Several mechanisms of the increased pulmonary arterial resistance in PPH have been proposed; however, the effect of intra-abdominal hypertension (IAH) due to massive splenomegaly on pulmonary circulation have not been evaluated.…”

Section: Introductionmentioning

confidence: 99%

Myelofibrosis‐associated massive splenomegaly: A cause of increased intra‐abdominal pressure, pulmonary hypertension, and positional dyspnea

et al. 2005

View full text Add to dashboard Cite

We describe a patient with myelofibrosis, giant splenomegaly, and pulmonary hypertension related to increased intra-abdominal pressure. Focusing on alterations in hemodynamic studies, we conclude that in patients with myelofibrosis, dyspnea, and hypoxemia, the measurement of intra-abdominal pressure should be included in the initial evaluation. It is an inexpensive, non-invasive diagnostic tool that can provide crucial information about the cause of dyspnea and disclose the pathogenetic link between massive splenomegaly and pulmonary compromise in myelofibrosis. Am.

show abstract

Functional and morphological cardiac changes in myeloproliferative disorders (clinical study)

Cited by 16 publications

References 30 publications

Prevalence and risk factors for Pulmonary Hypertension associated with chronic Myeloproliferative Neoplasms

Prevalence and risk factors for Pulmonary Hypertension associated with chronic Myeloproliferative Neoplasms

Comparative Assessment of Echocardiographic Patterns Among Chronic Myeloid Leukemia Patients on Tyrosine Kinase Inhibitor and Healthy Controls

Myelofibrosis‐associated massive splenomegaly: A cause of increased intra‐abdominal pressure, pulmonary hypertension, and positional dyspnea

Contact Info

Product

Resources

About